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Introduction: The objective was to study whether α-synuclein oligomers are altered in the cerebrospinal fluid (CSF)
of patients with dementia, including Parkinson disease with dementia (PDD), dementia with Lewy bodies (DLB), and
Alzheimer disease (AD), compared with age-matched controls.
Methods: In total, 247 CSF samples were assessed in this study, including 71 patients with DLB, 30 patients with
PDD, 48 patients with AD, and 98 healthy age-matched controls. Both total and oligomeric α-synuclein levels were
evaluated by using well-established immunoassays.
Results: The levels of α-synuclein oligomers in the CSF were increased in patients with PDD compared with the
controls (P < 0.05), but not in patients with DLB compared with controls. Interestingly, the levels of α-synuclein
oligomers in the CSF were also significantly higher in patients with PDD (P < 0.01) and DLB (P < 0.05) compared
with patients with AD. The levels of CSF α-synuclein oligomers and the ratio of oligomeric/total-α-synuclein could
distinguish DLB or PDD patients from AD patients, with areas under the curves (AUCs) of 0.64 and 0.75, respectively.
In addition, total-α-synuclein alone could distinguish DLB or PDD patients from AD patients, with an AUC of 0.80.
Conclusions: The levels of α-synuclein oligomers were increased in the CSF from α-synucleinopathy patients with
dementia compared with AD cases.Introduction
Alzheimer disease (AD) is the most common form of
dementia, and with an increasingly aged population, AD is
predicted to increase worldwide, causing suffering for the
patients and their families and a large cost for society
[1-3]. Other relatively common neurodegenerative disor-
ders that cause dementia are dementia with Lewy bodies
(DLB) and Parkinson disease with dementia (PDD). The
symptoms and neuropathologies of these dementia disor-
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reproduction in any medium, provided the oraccumulation of intraneuronal depositions of hyperpho-
sphorylated tau (neurofibrillary tangles) and extracellular
aggregates of β-amyloid (amyloid plaques) [3]. DLB and
PDD, however, are α-synucleinopathies that are charac-
terized by intraneuronal aggregates consisting mainly of
α-synuclein fibrils, which are found in Lewy bodies (LBs)
and Lewy neuritis [4]. However, amyloid accumulation
often also occurs in patients with DLB, and an AD-like
pathology can also be found in patients with PDD. In
addition, many AD cases also develop LBs [5,6].
The oligomerization of β-amyloid and α-synuclein
appear to be key events in the pathology of AD and DLB/
PDD, respectively [4]. Currently, several ongoing studies
are addressing potential disease-modifying treatments that
are directed against pathology-specific mechanisms, such
as the aggregation and formation of the neurotoxicl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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markers that can determine which brain pathologies
underlie the symptoms of an individual patient, instead of
classifying patients according to clinical syndromes, will
be very helpful when selecting patients with early symp-
toms for new clinical trials to evaluate new disease-
modifying therapies.
Biomarkers are available to aid in the diagnosis of AD,
and several studies have shown that β-amyloid1-42
(Aβ1-42) level is decreased and that the total tau (t-tau)
and phosphorylated tau (p-tau) levels are increased in
the cerebrospinal fluid (CSF) of patients with AD com-
pared with cognitively healthy controls [8-11].
Some studies have shown that the total levels of α-
synuclein in the CSF are significantly decreased in
patients with PD or DLB compared with patients with
AD [12-14], but other groups have reported conflicting
results [15-17]. During recent years, it has become in-
creasingly evident that early aggregates or “soluble oligo-
mers” of α-synuclein play an important role in the
pathogenesis of α-synucleinopathies rather than the late
aggregates or “amyloid fibrils.” Thus, high levels of soluble
α-synuclein oligomers are present in the brain homoge-
nates of patients with PD and DLB [18,19]. More recent
studies have shown that the oligomeric forms of α-synu-
clein are neurotoxic in vitro and in vivo [20-23]. We and
others recently reported elevated levels of α-synuclein
oligomers and an increased oligomer/total-α-synuclein
ratio in the CSF of PD patients compared with controls
[24,25]. These findings suggested that CSF α-synuclein
oligomers could be useful biomarkers for the diagnosis
and early detection of PD [24,25].
We studied the levels of CSF α-synuclein oligomers in
dementia cases with LBs compared with the levels in
dementia cases with AD and in healthy elderly controls.
Methods
Study participants
In the present study, we included 247 CSF samples from
subjects with AD (n = 48), PDD (n = 30), and DLB (n = 71)
and from nondemented elderly controls (n = 98) at the
Memory Clinic, Skåne University Hospital, Sweden. All
patients underwent brain imaging; routine laboratory
testing; and detailed neurologic, psychiatric and cognitive
examinations by a medical doctor experienced in de-
mentia disorders. Patients diagnosed with PDD met the
Clinical Diagnostic Criteria for Dementia Associated with
PD according to Emre et al. [26]. Patients who received
an AD diagnosis met the DSM-IIIR criteria for de-
mentia [27]. The criteria for probable AD were defined by
NINCDS-ADRDA [28]. Patients with DLB met the
consensus criteria according to McKeith et al. [29].
All controls underwent cognitive testing and neurologic
examination by a medical doctor, and individuals withobjective cognitive or parkinsonian symptoms were not
included as controls in the present study.
All individuals gave informed consent either by use
of a passive-consent procedure in which consent for
the retrospective use of banked clinical samples and
data was assumed if individuals did not actively retract
permission, as instructed in local press advertisements, or
by active written informed consent. This study procedure
was approved by the local ethics committee at Lund
University Sweden and conducted according to the
Helsinki Declaration.
CSF samples
The CSF samples were obtained by lumbar puncture in
the L3/L4 or L4/L5 interspace in the morning from non-
fasted patients. The samples were collected in polypro-
pylene tubes and gently mixed to avoid gradient effects.
All samples were centrifuged within 30 minutes at 4°C
at 2,000 g for 10 minutes to remove the cells and debris
and then stored in aliquots at −80°C until the biochem-
ical analysis.
Immunoassay for measuring oligomeric α-synuclein in the
CSF
A 384-well ELISA microplate was coated by overnight
incubation at 4°C with 1 μg/ml mAb 211 (Santa Cruz
Biotechnology, USA) in 200 mM NaHCO3, pH 9.6
(50 μl/well). The plate was washed with phosphate-buff-
ered saline (PBS) containing 0.05% Tween-20 (PBST) and
incubated with 100 μl/well of blocking buffer (PBS con-
taining 2.5% gelatin and 0.05% Tween-20) for 2 hours at
37°C. After washing, 50 μl of the CSF samples (thawed on
ice before Tween-20 was added to a final concentration of
0.05%) was added to each well, and then the plate was
incubated at 37°C for another 3 hours. Biotinylated 211
diluted to 1 μg/ml in blocking buffer was added, and
the plate was incubated at 37°C for 2 hours. The plate
was washed and then incubated for 1 hour at 37°C with
50 μl/well of ExtrAvidin-Peroxidase (Sigma-Aldrich, Dorset,
UK). After washing, the plate was incubated with 50 μl/well
of an enhanced chemiluminescent substrate (SuperSignal
ELISA Femto; Pierce Biotechnology, Rockford, IL, USA).
Then the chemiluminescence in relative light units was
immediately measured with a Victor3 1420 (Wallac) mi-
croplate reader [30,31]. The samples were screened in a
blind fashion and tested randomly. The case and control
samples were run on a single plate to avoid plate-to-plate
variations, and the results were confirmed with at least
two independent experiments.
Analysis of total levels of α-synuclein in CSF samples
The levels of total α-synuclein were quantified by using a
newly developed bead-based xMAP technology assay, and
these results were included in a previous report [14]. In
Hansson et al. Alzheimer's Research & Therapy 2014, 6:25 Page 3 of 6
http://alzres.com/content/6/3/25brief, a monoclonal antibody (MAb), 9B6 IgG1, which
recognizes a human-specific α-synuclein C-terminal epi-
tope in exon 5, was used as the capture antibody. The
antibody was covalently coupled to carboxylated beads
(region 126). The MAb 4D8 IgG1, an antibody recog-
nizing an N-terminal epitope in exon 3 of α-synuclein,
was used as the detector in its biotinylated form. The bead
assay was combined with bead-controlling heterophilic
antibody interference (a specific MAb, bead 150) [32].
Heterophilic antibodies are a common problem in immu-
noassays [33] and have been used to exclude samples in
plasma studies [34]. Although the problem of heterophilic
antibodies has also been acknowledged in CSF studies
[35], heterophilic antibodies were not observed in any of
the 247 CSF samples analyzed herein, by using an arbi-
trary cut-off of an MFI of 150. The assays were analyzed
on a Luminex 100IS instrument.Statistical analysis
The statistical analyses were conducted with SPSS for
Windows, version 20.0 (SPSS Inc., Chicago, IL, USA).
The correlation analyses were performed by using the
Spearman rank correlation test (Rs). To compare the
demographic and CSF baseline data between groups, the
Mann–Whitney U test was used for continuous vari-
ables, and the Pearson χ2 test was used for dichotomous
variables.Results
The levels of oligomeric and total α-synuclein in the
CSF samples
Both total and oligomeric forms of α-synuclein were
assessed in the CSF samples from 71 DLB patients, 30 PDD
patients, 48 AD patients, and 98 healthy elderly controls.





Age, years 69 (11.6) 76 (5.5)a
MMSE 29 (28–30) 23.5 (17–25)a
α-Synuclein oligomers 37,882 (21,763–136,685) 73,309 (36,361–3
α-Synuclein oligomers/
α-Synuclein total
549 (372–2149) 1,333 (492–5,973
α-Synuclein total 67.00 (52.00–86.00) 61.50 (51.25–68.
The data are presented as the median (25th to 75th percentile), except for age, wh
mean (SD). The α-synuclein oligomer levels are presented in RLU. The total α-synuc
oligomers/α-synuclein total, only CSF samples with hemoglobin less than 1,000 ng/
a,bCompared with the controls, aP < 0.001, bP < 0.05.
cCompared with PDD patients, cP < 0.001.
d, eCompared with DLB patients, dP < 0.001, eP < 0.05.The levels of α-synuclein oligomers in the CSF were in-
creased in patients with PDD compared with the controls
(P < 0.05; see Table 1 and Figure 1), but not in patients
with DLB compared with controls. Interestingly, the CSF
levels of the α-synuclein oligomers were also higher in
both the PDD and DLB patients compared with the AD
cases (P < 0.01 and P < 0.05, respectively; see Table 1 and
Figure 1A). Similarly, the ratio of α-synuclein oligomers/
total-α-synuclein was also elevated in patients with PDD
and DLB compared with the ratio in patients with AD
(P < 0.01; see Table 1 and Figure 1B).
Diagnostic accuracy of the oligomeric and total α-synuclein
Both CSF α-synuclein oligomers levels and the α-synu-
clein oligomers/total-α-synuclein ratio could distinguish
DLB and PDD patients from AD patients, with AUCs of
0.64 and 0.75, respectively. However, in this cohort, the
diagnostic accuracy of the CSF total α-synuclein levels
was even higher, with an AUC of 0.80 (Figure 2).
Associations between oligomeric α-synuclein and
cognitive performance
No significant correlations were found between the CSF
α-synuclein oligomers levels and the cognitive perform-
ance, as measured with the MMSE in the PDD patients,
DLB patients, and healthy controls. However, in the AD
cases, increased levels of α-synuclein oligomers in the
CSF correlated with worse performance on the MMSE
(Rs = −0.31; P < 0.05).
No correlations appeared between the CSF α-synuclein
oligomers and either age, gender, or disease duration (data
not shown).
Discussion
The discovery of missense and multiplication mutations
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Figure 1 Levels of α-synuclein oligomers (A; RLU, relative
luminescence units) and the ratio of α-synuclein oligomers to
total-α-synuclein (B; oligomer/total ratio, %) in the CSF of
healthy elderly individuals (n = 98) and of patients with PDD
(n = 30), DLB (n = 71) or AD (n = 48). The levels of α-synuclein
oligomers and the ratio were increased in patients with PDD compared
with patients with AD and healthy controls (Mann–Whitney U test;
P < 0.05). The box represents the interquartile range (IQR), with the
median indicated in the middle. The error bars represent the lowest















Oligomeric α-syn, AUC = 0.64 (0.55-0.74)
Total -syn, AUC = 0.82 (0.75-0.90)
The oligomeric/total, AUC = 0.75 (0.66-0.84)
AD vs DLB and PDD
Figure 2 Receiver operating characteristic curves (ROC) showing
the diagnostic accuracy of α-synuclein oligomers levels (black),
the ratio of α-synuclein oligomers/total-α-synuclein (red) and
total-α-synuclein levels (blue) when differentiating patients with
DLB and PDD from patients with AD.
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highlighted the direct role of α-synuclein overexpression
in the pathogenesis of these disorders. Furthermore, ab-
normal aggregates of α-synuclein protein were identified
as the main components of LBs, the pathologic hallmark
of PD, PDD, and DLB [40]. Therefore, α-synuclein mis-
folding and aggregation in the brain are considered
pivotal factors in the degeneration process. Early aggre-
gates or “soluble oligomers” of α-synuclein may be the
pathogenic species that lead to neuronal death and neu-
rodegeneration, rather than the late aggregates “amyloid
fibrils” [21,22]. High levels of α-synuclein oligomers
are present in brain homogenates from patients withPD and DLB compared with normal brains [18,19]. Inter-
estingly, we and others previously reported significant
differences between the CSF α-synuclein oligomers in PD
patients compared with age-matched controls, with most
of the PD samples showing higher levels of CSF α-synu-
clein oligomers than did age-matched controls [24,25].
The aim of this study was to determine whether α-sy-
nuclein oligomers levels and α-synuclein oligomers/
total-α-synuclein ratio in the CSF are elevated in α-
synucleinopathies cases with dementia compared with AD
patients and elderly healthy controls. In the present study,
we reported CSF levels of the oligomeric α-synuclein in
PDD, DLB, and AD cases. Interestingly, we observed high
levels of CSF α-synuclein oligomers and high α-synuclein
oligomers/total-α-synuclein ratio in PDD and DLB, which
was evident when compared with CSF samples from
patients with AD (Figure 1). We found no associations
between the CSF levels of the oligomeric α-synuclein and
cognitive performance in patients with PDD or DLB.
In contrast, AD patients with higher levels of CSF
α-synuclein oligomers exhibited a worse cognitive perfor-
mance, although the correlation was very weak, indicating
that AD patients with LB pathology could develop more
severe dementia.
Currently, distinguishing dementia patients with AD
from those patients with DLB relies on a clinical history
and examination. However, to design a better treatment
plan, objective methods to discriminate AD cases from
DLB cases are needed. For example, the neuroleptic
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toms in AD can be detrimental to DLB patients. Because
of the overlapping pathologies between these two dis-
orders, the standard CSF biomarkers for AD (Aβ1–42,
T-tau, and P-tau) do not readily discriminate between
them [41-44]. Future large clinical studies are needed
to evaluate whether CSF α-synuclein oligomers, when
combined with biomarkers for AD, could increase the
diagnostic precision in distinguishing dementia patients
with AD from those patients with DLB and PDD.
We believe that the α-synuclein oligomers detected in
CSF are derived from the neurons of the central nervous
system. Therefore, the concentration of the oligomeric
forms of α-synuclein in the CSF would correlate with
the levels of soluble α-synuclein aggregates that are
present in the brain. To address this issue, CSF studies
with neuropathologic outcomes are needed. CSF α-synu-
clein oligomers might, however, serve as markers for
selecting the correct patient population for clinical trials
that are designed to evaluate new experimental therapies
targeting α-synuclein oligomers in the brain. Selected
patients with high levels of CSF α-synuclein oligomers
could be more likely to respond to such therapies [7].
Moreover, the quantification of the levels of CSF α-
synuclein oligomers at the baseline and during the treat-
ment would assist with the identification of the most
promising and effective drug candidates and doses in
large-scale clinical trials.
Conclusions
In summary, our results demonstrated that the levels of
α-synuclein oligomers and oligomers/total-α-synuclein
ratio in the CSF are increased in patients with dementia
and LBs pathology. However, our findings need further
validation by independent studies in independent cohorts
with neuropathlogical outcome data.
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